2025 FRENCH GENOMIC
MEDICINE INITIATIVE

Genomic medicine is profoundly changing patient care. To ensure that everyone can access new technologies equitably throughout the country, France is putting in place a plan: the French genomic medicine initiative 2025. It aims to change by 2025 the way of diagnosing, prevent and treat patients.

PREINDICATIONS

The preindications for genomic sequencing set out the eligibility criteria for referring patients for genomic medicine tests. The list of preindications for which patients may undergo genomic sequencing during their care pathway is expanding over time.

TRANSVERSAL ACTIONS

PFMG2025 is based on cross-cutting initiatives designed to ensure the coherent and sustainable roll-out of genomic medicine in France. These foundational initiatives support the training of professionals, provide a framework for ethical and regulatory considerations, assess the medico-economic impacts, engage the industrial ecosystem and strengthen international cooperation.

RESEARCH AND ACCESS TO DATA

The reuse of PFMG2025 data for research is part of the open science movement. The aim is to make the data as widely accessible as possible, whilst ensuring its security and complying with a number of scientific and ethical criteria.

PFMG2025 INFRASTRUCTURES

INTERNATIONAL AFFAIRS

INFORMATION NOTICES

Information notices are available in English read more

Find the list of preindications in English read more

4 major issues

Organization of public health

Genomic medicine is revolutionising patient care pathways. Routine genome sequencing enables patients to receive personalised diagnostic and therapeutic care. This already applies to patients affected by certain rare diseases or cancers; ultimately, the aim of PFMG2025 is to extend access to genomic sequencing and personalised care to patients with more common diseases.

Scientific and clinical prospects

The aim is to structure and strengthen the continuum between care and research by accelerating research through the reuse of genomic data to improve understanding of diseases and develop new treatments, then transferring this new knowledge to care in order to improve diagnosis and patient management.

Technological progress

New technologies are set to converge with life and health sciences. The ability to acquire, store, distribute, match and interpret massive genomic data is at the heart of this convergence.

Economic dimension

Finally, there is an economic challenge, not only in terms of the sustainability of costs for our healthcare system, but also as a strategic opportunity to develop and structure a new industrial sector around partners already present in the field.